<DOC>
	<DOC>NCT02395601</DOC>
	<brief_summary>First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.</brief_summary>
	<brief_title>A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<criteria>Adults (aged ≥ 18 years) Histologically confirmed diagnosis of a Bcell lymphoma that has progressed in spite of prior treatment, and for which additional effective standard therapy is not available Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Adequate hematological, renal, hepatic, and coagulation laboratory assessments Must give written informed consent to participate in this study before the performance of any studyrelated procedure A primary lymphoma of the central nervous system (CNS) or known lymphomatous involvement of the CNS Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI1205, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade &gt;1 Treatment with proton pump inhibitors, H2 antagonists, or antacids Achlorhydria, either documented or suspected on the basis of an associated disease (e.g., pernicious anemia, atrophic gastritis, or certain gastric surgical procedures) Impaired cardiac function or clinically significant cardiac diseases, including any of the following: Acute myocardial infarction or angina pectoris ≤ 6 months prior to starting study drug New York Heart Association Class III or IV congestive heart failure QTcF &gt; 470 msec on the screening ECG Uncontrolled cardiac arrhythmia (patients with ratecontrolled atrial fibrillation are not excluded) A past medical history of other clinically significant cardiovascular disease (e.g., uncontrolled hypertension, history of labile hypertension or history of poor compliance with an antihypertensive regimen) Any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study (e.g., clinically significant pulmonary disease, clinically significant neurological disorder, active or uncontrolled infection) Systemic anticancer treatment or radiotherapy less than 2 weeks before the first dose of CPI 1205 Radioimmunotherapy (e.g., 131Itositumomab, 90Yibritumomab tiuxetan) less than 6 weeks before the first dose of CPI1205 Treatment with an investigational small molecule less than 2 weeks before the first dose of CPI1205. Treatment with a therapeutic antibody less than 4 weeks before the first dose of CPI1205. Treatment with medications that are strong inhibitors of CYP3A4 Treatment with medications that are inducers of CYP3A4 enzymes Treatment with medications that are known to carry a risk of Torsades de Pointes Pregnant or lactating women Women of child bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafter Patients unwilling or unable to comply with this study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>B-Cell Lymphoma</keyword>
	<keyword>EZH2 Inhibitor</keyword>
	<keyword>Phase 1</keyword>
</DOC>